181 related articles for article (PubMed ID: 12544505)
21. The value of 18F-FDG PET/CT imaging in breast cancer staging.
Yararbas U; Avci NC; Yeniay L; Argon AM
Bosn J Basic Med Sci; 2018 Feb; 18(1):72-79. PubMed ID: 28763628
[TBL] [Abstract][Full Text] [Related]
22. Clinical application of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in breast cancer.
Bernsdorf M; Graff J
Clin Physiol Funct Imaging; 2014 Nov; 34(6):426-33. PubMed ID: 24267489
[TBL] [Abstract][Full Text] [Related]
23. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
[TBL] [Abstract][Full Text] [Related]
24. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M
J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207
[TBL] [Abstract][Full Text] [Related]
25. FDG-PET for axillary lymph node staging in primary breast cancer.
Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
[TBL] [Abstract][Full Text] [Related]
26. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET.
Eubank WB; Mankoff DA; Vesselle HJ; Eary JF; Schubert EK; Dunnwald LK; Lindsley SK; Gralow JR; Austin-Seymour MM; Ellis GK; Livingston RB
Radiographics; 2002; 22(1):5-17. PubMed ID: 11796893
[TBL] [Abstract][Full Text] [Related]
27. Imaging of gynecologic malignancies with FDG PET-CT: case examples, physiologic activity, and pitfalls.
De Gaetano AM; Calcagni ML; Rufini V; Valentini AL; Gui B; Giordano A; Bonomo L
Abdom Imaging; 2009 Nov; 34(6):696-711. PubMed ID: 18791682
[TBL] [Abstract][Full Text] [Related]
28. Positron emission tomography in gastric and esophageal cancer.
Flamen P
Curr Opin Oncol; 2004 Jul; 16(4):359-63. PubMed ID: 15187891
[TBL] [Abstract][Full Text] [Related]
29. PET imaging in breast cancer.
Bombardieri E; Crippa F
Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
[TBL] [Abstract][Full Text] [Related]
30. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer.
Nieweg OE; Kim EE; Wong WH; Broussard WF; Singletary SE; Hortobagyi GN; Tilbury RS
Cancer; 1993 Jun; 71(12):3920-5. PubMed ID: 8389655
[TBL] [Abstract][Full Text] [Related]
31. Positron emission tomography for the diagnosis of breast cancer.
Rosé C; Dose J; Avril N
Nucl Med Commun; 2002 Jul; 23(7):613-8. PubMed ID: 12089482
[TBL] [Abstract][Full Text] [Related]
32. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].
Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R
Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489
[TBL] [Abstract][Full Text] [Related]
33. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
34. Position of nuclear medicine modalities in the diagnostic work-up of breast cancer.
Buscombe JR; Holloway B; Roche N; Bombardieri E
Q J Nucl Med Mol Imaging; 2004 Jun; 48(2):109-18. PubMed ID: 15243412
[TBL] [Abstract][Full Text] [Related]
35. Accuracy of 18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma.
Leblanc E; Gauthier H; Querleu D; Ferron G; Zerdoud S; Morice P; Uzan C; Lumbroso S; Lecuru F; Bats AS; Ghazzar N; Bannier M; Houvenaeghel G; Brenot-Rossi I; Narducci F
Ann Surg Oncol; 2011 Aug; 18(8):2302-9. PubMed ID: 21347790
[TBL] [Abstract][Full Text] [Related]
36. Advantages and limitations of FDG PET in the follow-up of breast cancer.
Lind P; Igerc I; Beyer T; Reinprecht P; Hausegger K
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S125-34. PubMed ID: 15085295
[TBL] [Abstract][Full Text] [Related]
37. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques.
Aukema TS; Rutgers EJ; Vogel WV; Teertstra HJ; Oldenburg HS; Vrancken Peeters MT; Wesseling J; Russell NS; Valdés Olmos RA
Eur J Surg Oncol; 2010 Apr; 36(4):387-92. PubMed ID: 19962268
[TBL] [Abstract][Full Text] [Related]
38. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes.
Nakajima N; Kataoka M; Sugawara Y; Ochi T; Kiyoto S; Ohsumi S; Mochizuki T
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):738-46. PubMed ID: 24064322
[TBL] [Abstract][Full Text] [Related]
39. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
[TBL] [Abstract][Full Text] [Related]
40. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience.
Hathaway PB; Mankoff DA; Maravilla KR; Austin-Seymour MM; Ellis GK; Gralow JR; Cortese AA; Hayes CE; Moe RE
Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]